TVRD Tvardi Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: TVRD
Price (delayed)
$4.22
Market cap
$39.57M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$16.18
Enterprise value
$19.18M
Relative Growth:
Rel. Growth:
27
Relative Strength:
Rel. Strength:
0
Relative Valuation:
Rel. Valuation:
11
Relative Profitability:
Rel. Profitability:
38
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in
Highlights
Tvardi Therapeutics's equity has soared by 184% YoY
TVRD's debt has dropped by 99% year-on-year and by 99% since the previous quarter
The quick ratio has dropped by 87% since the previous quarter and by 7% year-on-year
The revenue has declined by 34% year-on-year
Key stats
What are the main financial stats of TVRD
Market
Valuations
Earnings
Shares outstanding
9.38M
Market cap
$39.57M
Enterprise value
$19.18M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.2
Price to sales (P/S)
5.29
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.91
Revenue
$6.58M
Gross profit
$6.58M
Operating income
-$28.41M
Net income
-$20.89M
EBIT
-$13.84M
EBITDA
-$13.45M
Free cash flow
-$31.58M
Per share
Balance sheet
Liquidity
EPS
-$16.18
EPS diluted
-$17.69
Free cash flow per share
-$3.83
Book value per share
$3.52
Revenue per share
$0.8
TBVPS
$5.26
Total assets
$43.75M
Total liabilities
$10.82M
Debt
$254,000
Equity
$32.93M
Working capital
$32.45M
Debt to equity
0.01
Current ratio
4.04
Quick ratio
3.84
Net debt/EBITDA
1.52
Margins
Efficiency
Dividend
EBITDA margin
-204.4%
Gross margin
100%
Net margin
-317.5%
Operating margin
-431.8%
Return on assets
-49.4%
Return on equity
N/A
Return on invested capital
-42%
Return on capital employed
-41.9%
Return on sales
-210.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TVRD stock price
How has the Tvardi Therapeutics stock price performed over time
Intraday
-3.87%
1 week
-11.72%
1 month
-89.51%
1 year
-59.73%
YTD
-77.02%
QTD
-89.17%
Financial performance
How have Tvardi Therapeutics's revenue and profit performed over time
Revenue
$6.58M
Gross profit
$6.58M
Operating income
-$28.41M
Net income
-$20.89M
Gross margin
100%
Net margin
-317.5%
TVRD's net income has soared by 79% YoY and by 35% QoQ
Tvardi Therapeutics's operating income has soared by 71% YoY but it has decreased by 6% from the previous quarter
TVRD's net margin has surged by 68% year-on-year and by 35% since the previous quarter
Tvardi Therapeutics's operating margin has soared by 56% YoY but it has decreased by 6% from the previous quarter
Price vs fundamentals
How does TVRD's price correlate with its fundamentals
Growth
What is Tvardi Therapeutics's growth rate over time
Valuation
What is Tvardi Therapeutics stock price valuation
P/E
N/A
P/B
1.2
P/S
5.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.91
Tvardi Therapeutics's EPS has soared by 74% YoY and by 17% from the previous quarter
Tvardi Therapeutics's equity has soared by 184% YoY
The P/B is 70% lower than the 5-year quarterly average of 4.0
TVRD's P/S is 45% below its last 4 quarters average of 9.7 and 43% below its 5-year quarterly average of 9.3
The revenue has declined by 34% year-on-year
Efficiency
How efficient is Tvardi Therapeutics business performance
Tvardi Therapeutics's ROS has soared by 78% YoY and by 45% from the previous quarter
TVRD's return on invested capital has surged by 72% year-on-year and by 26% since the previous quarter
TVRD's ROA is up by 49% YoY and by 24% QoQ
Dividends
What is TVRD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TVRD.
Financial health
How did Tvardi Therapeutics financials performed over time
Tvardi Therapeutics's current ratio has plunged by 88% from the previous quarter and by 12% YoY
The quick ratio has dropped by 87% since the previous quarter and by 7% year-on-year
TVRD's debt is 99% smaller than its equity
Tvardi Therapeutics's equity has soared by 184% YoY
The company's debt to equity has surged by 100% QoQ but it has shrunk by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.